Moxaverine hydrochloride is a analogue of papaverine, a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma. References: Schmidl D, Pemp B, Lasta M, Boltz A, Kaya S, Palkovits S, Prager F, Schmetterer L, Garhofer G. Effects of orally administered moxaverine on ocular blood flow in healthy subjects. Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):515-20. doi: 10.1007/s00417-012-2207-1. Epub 2012 Dec 1. PubMed PMID: 23203292.

纯度：≥98%

CAS：1163-37-7